At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 354 enrolled
Drug / intervention
13-Valent Pneumococcal Conjugate Vaccine (13vPnC) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Brazil
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted May 12, 2008·Updated Aug 8, 2011
In Brief
A Phase 3 clinical trial evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) and 7-Valent Pneumococcal Conjugate Vaccine (7vPnc) for Vaccines, Pneumococcal Conjugate Vaccine. Completed, enrolled 354 participants across 4 sites.
Detailed Summary
The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccines, Pneumococcal Conjugate Vaccine
CountriesBrazil
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionSep 2009
TodayJul 2026
First PostedMay 12, 2008
Enrollment StartApr 1, 2008
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.1 years ago
Interventions
13-Valent Pneumococcal Conjugate Vaccine (13vPnC)biological
7-Valent Pneumococcal Conjugate Vaccine (7vPnc)biological